Privo Technologies, Inc. (Privo), a phase three clinical-stage biopharmaceutical company, announced on Thursday that it has named Dr Albert Collinson as its Independent Non-Executive Director.

Collinson is a former Business Development Advisor to Privo Technologies. He has more than 35 years of experience in the pharmaceutical and biotechnology industries, and served as the president and chief executive officer at Theracos, Inc. He founded and worked as president and chief executive officer of Opsonic Therapeutics, and has worked as the chief business officer of Rib-X Pharmaceuticals, senior vice president of business development at Phylos, Inc and vice president of global research & development licensing at BASF Pharma. He started his career as a scientist at ImmunoGen, Inc.

Dr Manijeh Goldberg, PhD., CEO and Founder of Privo Technologies Inc, said, 'Dr Collinson's appointment to our board of directors is a momentous occasion for Privo Technologies. We are thrilled to welcome him as an independent non-executive director. His unrivaled expertise and extensive industry network will undoubtedly enhance our ability to drive innovation and unlock new opportunities in the life sciences sector. We look forward to leveraging his insights and strategic guidance as we continue to advance our mission of improving human health through cutting-edge technologies.'